Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Selinexor in Advanced Liposarcoma

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Karyopharm Therapeutics Inc

Stanford Investigator(s):

Intervention(s):

  • Drug: Selinexor
  • Drug: Placebo

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   1. Patients ≥12 years of age

   2. Body surface area (BSA) ≥ 1.2 m2

   3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of
   DDLS requiring treatment

   4. Must have measurable disease per RECIST v1.1 Response Criteria

   5. Radiologic evidence of disease progression within 6 months prior to randomization. If
   the patient received other intervening therapy after documented disease progression,
   further disease progression must be documented after the completion of the intervening
   therapy

   6. Must have had at least two (2) prior lines of systemic therapy for liposarcoma (not to
   exceed 5 prior lines)

   7. If patient received any previous systemic therapy, the last dose must have been ≥ 21
   days prior to randomization (or ≥ 5 half-lives of that drug - whichever is shorter)
   with all clinically significant therapy- related toxicities having resolved to less
   than or equal to Grade 1

Exclusion Criteria:

   1. Patients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.

   2. Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus
   (HIV) infection.

   3. Known central nervous system metastases

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting